- Home
- News
- Treatment & Care
- HIV Worldwide
- Living with HIV
- Preventing HIV
- Organisations
- HIV Basics
- About Us
Patient Information Booklets
- What is lipodystrophy?
- Who will develop body fat changes?
- HIV treatment and body fat changes
- Do particular drugs cause body fat changes?
- Should I be worried about body fat changes?
- Preventing and treating body fat changes
- Treating fat gain
- Exercise and body fat changes
- How does exercise affect the different body fat changes?
- Treating fat loss
- HIV, HIV treatment and changes in your metabolism
- Heart disease and anti-HIV drugs
- Treatment for metabolic changes
- Stopping smoking
- Lipid lowering drugs
- Drugs to normalise or control glucose and insulin
- Summary
Summary
- Lipodystrophy refers to changes in body fat and the metabolism of fat and sugar seen in people with HIV, mainly in people taking protease inhibitors and nucleoside analogues (NRTIs) together.
- d4T and to a lesser extent AZT have been associated with fat loss.
- Changing from d4T or AZT to abacavir or tenofovir can lead to a very slow improvement in fat loss. Exercise has been shown to improve central fat and metabolic problems.
- Facial fat loss may be improved by injections of a substance called polylactic acid. This is available on the NHS at some, but not all clinics.
- Cholesterol, triglyceride and glucose levels may rise after you start combination therapy. If you have existing heart disease, or several risk factors for heart disease, your doctor may suggest treatment to reduce these levels.
- The significance of metabolic changes in people without major risk factors for heart disease is still unknown.